;PMID: 10353750
;source_file_1301.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..38] = [t:0..38]
;1)sentence:[e:43..217] = [t:43..217]
;2)section:[e:221..294] = [t:221..294]
;3)section:[e:298..407] = [t:298..407]
;4)sentence:[e:411..583] = [t:411..583]
;5)sentence:[e:584..650] = [t:584..650]
;6)sentence:[e:651..771] = [t:651..771]
;7)sentence:[e:772..817] = [t:772..817]
;8)sentence:[e:818..903] = [t:818..903]
;9)sentence:[e:904..1003] = [t:904..1003]
;10)sentence:[e:1004..1081] = [t:1004..1081]
;11)sentence:[e:1082..1178] = [t:1082..1178]
;12)sentence:[e:1179..1351] = [t:1179..1351]
;13)sentence:[e:1352..1562] = [t:1352..1562]
;14)sentence:[e:1563..1631] = [t:1563..1631]
;15)sentence:[e:1632..1760] = [t:1632..1760]
;16)section:[e:1764..1809] = [t:1764..1809]

;section 0 Span:0..38
;Clin Cancer Res  1999 May;5(5):1147-53
(SEC
  (FRAG (NNP:[0..4] Clin) (NNP:[5..11] Cancer) (NNP:[12..15] Res)
        (CD:[17..21] 1999) (NNP:[22..25] May) (::[25..26] ;) (CD:[26..27] 5)
        (-LRB-:[27..28] -LRB-) (CD:[28..29] 5) (-RRB-:[29..30] -RRB-)
        (::[30..31] :) (CD:[31..35] 1147) (::[35..36] -) (CD:[36..38] 53)))

;sentence 1 Span:43..217
;Detection of mutations of p53 tumor suppressor gene in pancreatic juice and
;its  application to diagnosis of patients with pancreatic cancer: comparison
;with  K-ras mutation.
;[69..72]:gene-rna:"p53"
;[166..183]:malignancy-type:"pancreatic cancer"
;[202..207]:gene-rna:"K-ras"
(SENT
  (NP-HLN
    (NP
      (NP
        (NP (NN:[43..52] Detection))
        (PP (IN:[53..55] of)
          (NP
            (NP (NNS:[56..65] mutations))
            (PP (IN:[66..68] of)
              (NP (NN:[69..72] p53)
                (NML (NN:[73..78] tumor) (NN:[79..89] suppressor))
                (NN:[90..94] gene)))))
        (PP-LOC (IN:[95..97] in)
          (NP (JJ:[98..108] pancreatic) (NN:[109..114] juice))))
      (CC:[115..118] and)
      (NP
        (NP (PRP$:[119..122] its) (NN:[124..135] application))
        (PP (TO:[136..138] to)
          (NP
            (NP (NN:[139..148] diagnosis))
            (PP (IN:[149..151] of)
              (NP
                (NP (NNS:[152..160] patients))
                (PP (IN:[161..165] with)
                  (NP (JJ:[166..176] pancreatic) (NN:[177..183] cancer)))))))))
    (::[183..184] :)
    (NP
      (NP (NN:[185..195] comparison))
      (PP (IN:[196..200] with)
        (NP (NN:[202..207] K-ras) (NN:[208..216] mutation))))
    (.:[216..217] .)))

;section 2 Span:221..294
;Yamaguchi Y, Watanabe H, Yrdiran S, Ohtsubo K, Motoo Y, Okai T, Sawabu N.
(SEC
  (FRAG (NNP:[221..230] Yamaguchi) (NNP:[231..232] Y) (,:[232..233] ,)
        (NNP:[234..242] Watanabe) (NNP:[243..245] H,) (NNP:[246..253] Yrdiran)
        (NNP:[254..255] S) (,:[255..256] ,) (NNP:[257..264] Ohtsubo)
        (NNP:[265..267] K,) (NNP:[268..273] Motoo) (NNP:[274..275] Y)
        (,:[275..276] ,) (NNP:[277..281] Okai) (NNP:[282..283] T)
        (,:[283..284] ,) (NNP:[285..291] Sawabu) (NNP:[292..293] N)
        (.:[293..294] .)))

;section 3 Span:298..407
;Department of Internal Medicine and Medical Oncology, Cancer Research
;Institute,  Kanazawa University, Japan.
(SEC
  (FRAG (NNP:[298..308] Department) (IN:[309..311] of) (NNP:[312..320] Internal)
        (NNP:[321..329] Medicine) (CC:[330..333] and) (NNP:[334..341] Medical)
        (NNP:[342..350] Oncology) (,:[350..351] ,) (NNP:[352..358] Cancer)
        (NNP:[359..367] Research) (NNP:[368..377] Institute) (,:[377..378] ,)
        (NNP:[380..388] Kanazawa) (NNP:[389..399] University) (,:[399..400] ,)
        (NNP:[401..406] Japan) (.:[406..407] .)))

;sentence 4 Span:411..583
;Because of the difficulty in obtaining biopsy specimens from pancreatic
;cancer  patients, K-ras mutation analysis in pancreatic juice has been used
;for specific  diagnosis.
;[472..489]:malignancy-type:"pancreatic cancer"
;[501..506]:gene-rna:"K-ras"
(SENT
  (S
    (PP (IN:[411..418] Because) (IN:[419..421] of)
      (NP
        (NP (DT:[422..425] the) (NN:[426..436] difficulty))
        (PP (IN:[437..439] in)
          (S-NOM
            (NP-SBJ (-NONE-:[439..439] *))
            (VP (VBG:[440..449] obtaining)
              (NP (NN:[450..456] biopsy) (NNS:[457..466] specimens))
              (PP (IN:[467..471] from)
                (NP
                  (NML (JJ:[472..482] pancreatic) (NN:[483..489] cancer))
                  (NNS:[491..499] patients))))))))
    (,:[499..500] ,)
    (NP-SBJ-1
      (NP
        (NML (NN:[501..506] K-ras) (NN:[507..515] mutation))
        (NN:[516..524] analysis))
      (PP-LOC (IN:[525..527] in)
        (NP (JJ:[528..538] pancreatic) (NN:[539..544] juice))))
    (VP (VBZ:[545..548] has)
      (VP (VBN:[549..553] been)
        (VP (VBN:[554..558] used)
          (NP-1 (-NONE-:[558..558] *))
          (PP (IN:[559..562] for)
            (NP (JJ:[563..571] specific) (NN:[573..582] diagnosis))))))
    (.:[582..583] .)))

;sentence 5 Span:584..650
;But recently, false positives have been obtained with this method.
(SENT
  (S (IN:[584..587] But)
    (ADVP-TMP (RB:[588..596] recently))
    (,:[596..597] ,)
    (NP-SBJ-1 (JJ:[598..603] false) (NNS:[604..613] positives))
    (VP (VBP:[614..618] have)
      (VP (VBN:[619..623] been)
        (VP (VBN:[624..632] obtained)
          (NP-1 (-NONE-:[632..632] *))
          (PP-MNR (IN:[633..637] with)
            (NP (DT:[638..642] this) (NN:[643..649] method))))))
    (.:[649..650] .)))

;sentence 6 Span:651..771
;To  improve the genetic diagnosis of pancreatic cancer, detection of p53 gene
; mutation in pancreatic juice was studied.
;[688..705]:malignancy-type:"pancreatic cancer"
;[720..723]:gene-rna:"p53"
(SENT
  (S
    (S-PRP
      (NP-SBJ (-NONE-:[651..651] *))
      (VP (TO:[651..653] To)
        (VP (VB:[655..662] improve)
          (NP
            (NP (DT:[663..666] the) (JJ:[667..674] genetic)
                (NN:[675..684] diagnosis))
            (PP (IN:[685..687] of)
              (NP (JJ:[688..698] pancreatic) (NN:[699..705] cancer)))))))
    (,:[705..706] ,)
    (NP-SBJ-1
      (NP (NN:[707..716] detection))
      (PP (IN:[717..719] of)
        (NP (NN:[720..723] p53) (NN:[724..728] gene) (NN:[730..738] mutation)))
      (PP-LOC (IN:[739..741] in)
        (NP (JJ:[742..752] pancreatic) (NN:[753..758] juice))))
    (VP (VBD:[759..762] was)
      (VP (VBN:[763..770] studied)
        (NP-1 (-NONE-:[770..770] *))))
    (.:[770..771] .)))

;sentence 7 Span:772..817
;Pancreatic juice was sampled  endoscopically.
(SENT
  (S
    (NP-SBJ-1 (JJ:[772..782] Pancreatic) (NN:[783..788] juice))
    (VP (VBD:[789..792] was)
      (VP (VBN:[793..800] sampled)
        (NP-1 (-NONE-:[800..800] *))
        (ADVP-MNR (RB:[802..816] endoscopically))))
    (.:[816..817] .)))

;sentence 8 Span:818..903
;Single-strand conformation polymorphism analysis was used for  p53 mutation
;analysis.
;[881..884]:gene-rna:"p53"
(SENT
  (S
    (NP-SBJ-1
      (NML
        (NML (JJ:[818..824] Single) (HYPH:[824..825] -) (NN:[825..831] strand))
        (NN:[832..844] conformation) (NN:[845..857] polymorphism))
      (NN:[858..866] analysis))
    (VP (VBD:[867..870] was)
      (VP (VBN:[871..875] used)
        (NP-1 (-NONE-:[875..875] *))
        (PP (IN:[876..879] for)
          (NP
            (NML (NN:[881..884] p53) (NN:[885..893] mutation))
            (NN:[894..902] analysis)))))
    (.:[902..903] .)))

;sentence 9 Span:904..1003
;Furthermore, K-ras mutations at codon 12 were also  studied in the same
;pancreatic cancer patients.
;[917..922]:gene-rna:"K-ras"
;[923..932]:variation-event:"mutations"
;[936..944]:variation-location:"codon 12"
;[976..993]:malignancy-type:"pancreatic cancer"
(SENT
  (S
    (ADVP (RB:[904..915] Furthermore))
    (,:[915..916] ,)
    (NP-SBJ-1
      (NP (NN:[917..922] K-ras) (NNS:[923..932] mutations))
      (PP-LOC (IN:[933..935] at)
        (NP (NN:[936..941] codon) (CD:[942..944] 12))))
    (VP (VBD:[945..949] were)
      (ADVP (RB:[950..954] also))
      (VP (VBN:[956..963] studied)
        (NP-1 (-NONE-:[963..963] *))
        (PP (IN:[964..966] in)
          (NP (DT:[967..970] the) (JJ:[971..975] same)
            (NML (JJ:[976..986] pancreatic) (NN:[987..993] cancer))
            (NNS:[994..1002] patients)))))
    (.:[1002..1003] .)))

;sentence 10 Span:1004..1081
;Of 26 cases of pancreatic  cancer, p53 mutations were detected in 11
;(42.3%).
;[1019..1037]:malignancy-type:"pancreatic  cancer"
;[1039..1042]:gene-rna:"p53"
(SENT
  (S
    (PP-TPC-1 (IN:[1004..1006] Of)
      (NP
        (NP (CD:[1007..1009] 26) (NNS:[1010..1015] cases))
        (PP (IN:[1016..1018] of)
          (NP (JJ:[1019..1029] pancreatic) (NN:[1031..1037] cancer)))))
    (,:[1037..1038] ,)
    (NP-SBJ-2 (NN:[1039..1042] p53) (NNS:[1043..1052] mutations))
    (VP (VBD:[1053..1057] were)
      (VP (VBN:[1058..1066] detected)
        (NP-2 (-NONE-:[1066..1066] *))
        (PP (IN:[1067..1069] in)
          (NP
            (NP (CD:[1070..1072] 11)
              (PRN (-LRB-:[1073..1074] -LRB-)
                (NP (CD:[1074..1078] 42.3) (NN:[1078..1079] %))
                (-RRB-:[1079..1080] -RRB-)))
            (PP-1 (-NONE-:[1080..1080] *T*))))))
    (.:[1080..1081] .)))

;sentence 11 Span:1082..1178
;No mutations were seen in the  cases with mucin-producing adenoma nor with
;chronic pancreatitis.
;[1124..1129]:gene-protein:"mucin"
;[1140..1147]:malignancy-type:"adenoma"
(SENT
  (S
    (NP-SBJ-1 (DT:[1082..1084] No) (NNS:[1085..1094] mutations))
    (VP (VBD:[1095..1099] were)
      (VP (VBN:[1100..1104] seen)
        (NP-1 (-NONE-:[1104..1104] *))
        (PP (IN:[1105..1107] in)
          (NP
            (NP (DT:[1108..1111] the) (NNS:[1113..1118] cases))
            (PP
              (PP (IN:[1119..1123] with)
                (NP
                  (ADJP (NN:[1124..1129] mucin) (HYPH:[1129..1130] -)
                        (VBG:[1130..1139] producing))
                  (NN:[1140..1147] adenoma)))
              (CC:[1148..1151] nor)
              (PP (IN:[1152..1156] with)
                (NP (JJ:[1157..1164] chronic) (NN:[1165..1177] pancreatitis))))))))
    (.:[1177..1178] .)))

;sentence 12 Span:1179..1351
;K-ras  mutations were detected in 84.0% of cases by RFLP analysis, which has
;high  sensitivity, and in 65.3% by hybridization protection assay, which has
;high  specificity.
;[1179..1184]:gene-rna:"K-ras"
(SENT
  (S
    (NP-SBJ-1 (NN:[1179..1184] K-ras) (NNS:[1186..1195] mutations))
    (VP (VBD:[1196..1200] were)
      (VP
        (VP (VBN:[1201..1209] detected)
          (NP-1 (-NONE-:[1209..1209] *))
          (PP=4 (IN:[1210..1212] in)
            (NP
              (NP (CD:[1213..1217] 84.0) (NN:[1217..1218] %))
              (PP (IN:[1219..1221] of)
                (NP (NNS:[1222..1227] cases)))))
          (PP-MNR=5 (IN:[1228..1230] by)
            (NP
              (NP (NN:[1231..1235] RFLP) (NN:[1236..1244] analysis))
              (,:[1244..1245] ,)
              (SBAR
                (WHNP-3 (WDT:[1246..1251] which))
                (S
                  (NP-SBJ-3 (-NONE-:[1251..1251] *T*))
                  (VP (VBZ:[1252..1255] has)
                    (NP (JJ:[1256..1260] high) (NN:[1262..1273] sensitivity))))))))
        (,:[1273..1274] ,) (CC:[1275..1278] and)
        (VP
          (PP=4 (IN:[1279..1281] in)
            (NP (CD:[1282..1286] 65.3) (NN:[1286..1287] %)))
          (PP-MNR=5 (IN:[1288..1290] by)
            (NP
              (NP
                (NML (NN:[1291..1304] hybridization)
                     (NN:[1305..1315] protection))
                (NN:[1316..1321] assay))
              (,:[1321..1322] ,)
              (SBAR
                (WHNP-2 (WDT:[1323..1328] which))
                (S
                  (NP-SBJ-2 (-NONE-:[1328..1328] *T*))
                  (VP (VBZ:[1329..1332] has)
                    (NP (JJ:[1333..1337] high) (NN:[1339..1350] specificity))))))))))
    (.:[1350..1351] .)))

;sentence 13 Span:1352..1562
;Using a combination assay with both genes, genetic abnormalities  were
;detected in 92.0% by RFLP and 73.1% by hybridization protection assay 
;including two cases in which p53 alone was positive by both methods.
;[1523..1526]:gene-rna:"p53"
(SENT
  (S
    (S-MNR
      (NP-SBJ (-NONE-:[1352..1352] *))
      (VP (VBG:[1352..1357] Using)
        (NP (DT:[1358..1359] a) (NN:[1360..1371] combination)
            (NN:[1372..1377] assay))
        (PP (IN:[1378..1382] with)
          (NP (DT:[1383..1387] both) (NNS:[1388..1393] genes)))))
    (,:[1393..1394] ,)
    (NP-SBJ-1 (JJ:[1395..1402] genetic) (NNS:[1403..1416] abnormalities))
    (VP (VBD:[1418..1422] were)
      (VP
        (VP (VBN:[1423..1431] detected)
          (NP-1 (-NONE-:[1431..1431] *))
          (PP (IN:[1432..1434] in)
            (NP=2 (CD:[1435..1439] 92.0) (NN:[1439..1440] %)))
          (PP-MNR=3 (IN:[1441..1443] by)
            (NP (NN:[1444..1448] RFLP))))
        (CC:[1449..1452] and)
        (VP
          (NP=2 (CD:[1453..1457] 73.1) (NN:[1457..1458] %))
          (PP-MNR=3 (IN:[1459..1461] by)
            (NP
              (NML (NN:[1462..1475] hybridization) (NN:[1476..1486] protection))
              (NN:[1487..1492] assay))))
        (PP (VBG:[1494..1503] including)
          (NP
            (NP (CD:[1504..1507] two) (NNS:[1508..1513] cases))
            (SBAR
              (WHPP-4 (IN:[1514..1516] in)
                (WHNP (WDT:[1517..1522] which)))
              (S
                (NP-SBJ
                  (NP (NN:[1523..1526] p53))
                  (ADJP (RB:[1527..1532] alone)))
                (VP (VBD:[1533..1536] was)
                  (ADJP-PRD (JJ:[1537..1545] positive))
                  (PP-MNR (IN:[1546..1548] by)
                    (NP (DT:[1549..1553] both) (NNS:[1554..1561] methods)))
                  (PP-4 (-NONE-:[1561..1561] *T*)))))))))
    (.:[1561..1562] .)))

;sentence 14 Span:1563..1631
;The  specificity of p53 mutation for pancreatic cancer is very high.
;[1583..1586]:gene-rna:"p53"
;[1600..1617]:malignancy-type:"pancreatic cancer"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1563..1566] The) (NN:[1568..1579] specificity))
      (PP (IN:[1580..1582] of)
        (NP (NN:[1583..1586] p53) (NN:[1587..1595] mutation)))
      (PP (IN:[1596..1599] for)
        (NP (JJ:[1600..1610] pancreatic) (NN:[1611..1617] cancer))))
    (VP (VBZ:[1618..1620] is)
      (ADJP-PRD (RB:[1621..1625] very) (JJ:[1626..1630] high)))
    (.:[1630..1631] .)))

;sentence 15 Span:1632..1760
;Therefore,  simultaneous analysis of p53 and K-ras mutation is suggested to
;enhance the  genetic diagnosis of pancreatic cancer.
;[1669..1672]:gene-rna:"p53"
;[1677..1682]:gene-rna:"K-ras"
;[1742..1759]:malignancy-type:"pancreatic cancer"
(SENT
  (S
    (ADVP (RB:[1632..1641] Therefore))
    (,:[1641..1642] ,)
    (NP-SBJ-2
      (NP (JJ:[1644..1656] simultaneous) (NN:[1657..1665] analysis))
      (PP (IN:[1666..1668] of)
        (NP
          (NP (NN:[1669..1672] p53)
            (NML-1 (-NONE-:[1672..1672] *P*)))
          (CC:[1673..1676] and)
          (NP (NN:[1677..1682] K-ras)
            (NML-1 (NN:[1683..1691] mutation))))))
    (VP (VBZ:[1692..1694] is)
      (VP (VBN:[1695..1704] suggested)
        (S
          (NP-SBJ-2 (-NONE-:[1704..1704] *))
          (VP (TO:[1705..1707] to)
            (VP (VB:[1708..1715] enhance)
              (NP
                (NP (DT:[1716..1719] the) (JJ:[1721..1728] genetic)
                    (NN:[1729..1738] diagnosis))
                (PP (IN:[1739..1741] of)
                  (NP (JJ:[1742..1752] pancreatic) (NN:[1753..1759] cancer)))))))))
    (.:[1759..1760] .)))

;section 16 Span:1764..1809
;PMID: 10353750 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1764..1768] PMID) (::[1768..1769] :) (CD:[1770..1778] 10353750)
        (NN:[1779..1780] -LSB-) (NNP:[1780..1786] PubMed) (::[1787..1788] -)
        (NN:[1789..1796] indexed) (IN:[1797..1800] for)
        (NNP:[1801..1809] MEDLINE-RSB-)))
